Healthcare [ 12/13 ] | Biotechnology [ 116/164 ]
NASDAQ | Common Stock
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.
The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.
It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors.
In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2.
It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform.
TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 24 | 0.00 Increased by +100.00% | -0.26 Increased by +100.00% |
| Mar 6, 24 | -0.21 Increased by +73.08% | -0.29 Increased by +27.59% |
| Nov 9, 23 | -0.24 Increased by +64.18% | -0.45 Increased by +46.67% |
| Aug 10, 23 | -0.51 Increased by +19.05% | -0.78 Increased by +34.62% |
| May 10, 23 | -0.93 Decreased by -38.81% | -0.74 Decreased by -25.68% |
| Mar 8, 23 | -0.78 Decreased by -105.26% | -0.70 Decreased by -11.43% |
| Nov 9, 22 | -0.67 Increased by +16.25% | -0.72 Increased by +6.94% |
| Aug 10, 22 | -0.63 Increased by +91.81% | -0.75 Increased by +16.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 7.21 M Increased by +721.00 K% | -19.61 M Decreased by -4.34% | Decreased by -271.99% Increased by +99.99% |
| Sep 30, 23 | 3.89 M Increased by +15.58% | -23.00 M Decreased by -44.53% | Decreased by -591.64% Decreased by -25.04% |
| Jun 30, 23 | 3.15 M Decreased by -22.39% | -24.05 M Decreased by -60.86% | Decreased by -763.82% Decreased by -107.25% |
| Mar 31, 23 | 6.80 M Increased by +125.19% | -22.56 M Decreased by -39.72% | Decreased by -331.66% Increased by +37.96% |
| Dec 31, 22 | 1.00 K Decreased by -99.96% | -18.80 M Decreased by -32.37% | Decreased by -1.88 M% Decreased by -377.69 K% |
| Sep 30, 22 | 3.36 M Increased by +39.43% | -15.91 M Decreased by -0.46% | Decreased by -473.15% Increased by +27.95% |
| Jun 30, 22 | 4.06 M Increased by +42.42% | -14.95 M Decreased by -40.04% | Decreased by -368.54% Increased by +1.67% |
| Mar 31, 22 | 3.02 M Increased by +49.04% | -16.15 M Decreased by -104.11% | Decreased by -534.56% Decreased by -36.95% |